Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioventus (BVS) Revenue (2020 - 2026)

Bioventus filings provide 6 years of Revenue readings, the most recent being $157.9 million for Q4 2025.

  • On a quarterly basis, Revenue rose 2.77% to $157.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $568.1 million, a 0.91% decrease, with the full-year FY2025 number at $568.1 million, down 0.91% from a year prior.
  • Revenue hit $157.9 million in Q4 2025 for Bioventus, up from $138.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $157.9 million in Q4 2025 to a low of $81.8 million in Q2 2021.
  • Median Revenue over the past 5 years was $129.9 million (2021), compared with a mean of $129.8 million.
  • Biggest five-year swings in Revenue: surged 89.28% in 2021 and later fell 6.12% in 2023.
  • Bioventus' Revenue stood at $130.4 million in 2021, then dropped by 3.51% to $125.8 million in 2022, then grew by 7.62% to $135.4 million in 2023, then rose by 13.45% to $153.6 million in 2024, then rose by 2.77% to $157.9 million in 2025.
  • The last three reported values for Revenue were $157.9 million (Q4 2025), $138.7 million (Q3 2025), and $147.7 million (Q2 2025) per Business Quant data.